US FDA advisory panel voted to endorse emergency use of COVID-19 vaccine from Pfizer and BioNTech
An advisory panel of the Food and Drug Administration in the United States (US FDA) on Thursday voted to endorse emergency use of COVID-19 vaccine from vaccine makers Pfizer and BioNTech.
This, as it paved the way for the Food and Drug Administration in the United States to authorize the jab for a nation that had lost over 285,000 lives to coronavirus disease.
The Food and Drug Administration in the United States was widely expected to authorize the COVID-19 vaccine that was jointly developed by Pfizer and BioNTech for an emergency use in the country within days.
In a report on GMA News Online, the committee voted 17-4 that the known benefits of the coronavirus vaccine outweighed the risks of taking the jab for individuals 16 and older, with one member of the panel abstaining.
As per the report, the panel voted on the question as put them by the Food and Drug Administration which included people ages 16 to 17 year old.
The Food and Drug Administration typically followed the advice of its expert panels, but wasn’t bound to do so.
In addition, the panel also tackled concerns raised by two reports of serious allergic reactions among COVID-19 vaccine recipients in the UK.
Documents prepared by the Food and Drug Administration ahead of the meeting didn’t point out any new safety or efficacy issues as it raised optimism that the United States would soon follow Britain and Canada authorizing the COVID-19 vaccine.